Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral, Thimerosal-Free (FluLaval TF), in Adults 18 to 60 Years of Age.

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral, Thimerosal-Free (FluLaval TF), in Adults 18 to 60 Years of Age.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2017

At a glance

  • Drugs GSK 1536489A (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 04 Dec 2008 Status changed from active, no longer recruiting to completed.
    • 30 Oct 2008 Planned end date changed to 1 Feb 2009 as reported by ClinicalTrials.gov.
    • 30 Oct 2008 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top